Novavax (NVAX) volatility elevated into Resolve trial failed its primary and secondary goals

September 16, 2016 5:51 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Novavax (NVAX) September call option implied volatility is at 190, October is at 215, January is at 138; compared to its 52-week range of 61 to 201 into its Resolve trial failed its primary and secondary goals.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Options, Trader Talk

Related Entities

Options

Add Your Comment